Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HTC-867 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HTC-867 | DRUG | - |
Inclusion: 1. Men aged 20 to 45 years inclusive at screening. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after test article administration. 2. Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weig...
HTC-867 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial that enrolled healthy Japanese male subjects to evaluate its safety and tolerability.
HTC-867 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical research on this investigational small molecule for the treatment of schizophrenia. The drug is currently in Phase 1 development.
HTC-867 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, which evaluated the safety and tolerability of the drug in healthy subjects.
HTC-867 has one completed clinical trial registered as NCT01268124. This Phase 1 study evaluated the safety and tolerability of HTC-867 in healthy Japanese subjects. The trial enrolled 56 participants and was completed. The study was randomized and double-blind, though it did not use a control group.
No alternative names for HTC-867 have been identified. The drug is known by its development code HTC-867 and is being studied by Pfizer for the treatment of schizophrenia. It is currently in Phase 1 clinical development.